1005342-94-8

Basic information

• Product Name: 4-bromo-pyridine-2-carboxylic acid N-methoxy-N-methyl-amide
• Synonyms: 4-bromo-pyridine-2-carboxylic acid N-methoxy-N-methyl-amide
• CAS NO: 1005342-94-8
• Molecular Weight: 245.076
• Mol File: 1005342-94-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-bromo-pyridine-2-carboxylic acid N-methoxy-N-methyl-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-pyridine-2-carboxylic acid N-methoxy-N-methyl-amide(1005342-94-8)
• EPA Substance Registry System: 4-bromo-pyridine-2-carboxylic acid N-methoxy-N-methyl-amide(1005342-94-8)

Safety Data

• Hazardous Substances Data: 1005342-94-8(Hazardous Substances Data)

Upstream product

• 29681-42-3 methyl 4-bromopyridine-2-carboxylate 
• 30766-03-1 4-bromo-2-picolinic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 4021-08-3 4-methylpicolinic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 131747-63-2 4-bromo-2-pyridinecarboxaldehyde 
• 1005342-97-1 4-bromo-2-{(1S,2S)-1-[1-(4-methoxyphenyl)ethyl]pyrrolidin-2-yl}-pyridine 
• 1596335-37-3 N-{2-[2-amino-7-(2-hydroxy-1,1,-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]pyridin-4-yl}-2-(4-chlorophenyl)acetamide 
• 1596335-36-2 2-(4-chlorophenyl)-N-[2-(7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)pyridin-4-yl]acetamide 

Relevant articles and documents

Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors

The transforming growth factor type β receptor I (TGF-β R1, also known as activin-like kinase 5 or ALK5) plays a significant role in the pathogenesis of multiple diseases such as malignant tumors and tissue fibrosis. Specific inhibition of ALK5 provides a novel method for controlling the development of cancers and fibrotic diseases. Herein, a novel series of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives was synthesized and identified as ALK5 inhibitors. Among them, compound 8h inhibited ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. Compound 8h also showed favorable pharmacokinetic profile and ameliorated hERG inhibition. More importantly, 30 mg/kg oral administration of 8h could significantly induce tumour growth inhibition in CT26 xenograft model without obvious toxicity.

SPIROCYCLIC COMPOUNDS

Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.